ArticleDrug design, development and therapy2026
PJ34 Prevents Trauma-Induced Heterotopic Ossification without Adverse Bone Healing: An in vivo and in vitro Investigation.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Trauma-induced heterotopic ossification (THO) is a complication characterized by ectopic lamellar bone formation in soft tissues after trauma. Current treatments are limited by low efficiency, recurrence, and potential impairment of bone healing, highlighting the need for new strategies. Mesenchymal stem cell (MSC) recruitment and osteogenic differentiation are critical in THO pathogenesis. Poly [ADP-ribose] polymerase 1 (PARP1) is involved in regulating osteogenic differentiation, and PJ34, a PARP1 inhibitor, may have potential in THO prevention. Methods: This study investigated PJ34's effects on THO and bone healing through in vitro and in vivo experiments. In vitro experiments, the effects of different concentrations of PJ34 on the proliferation, recruitment, migration, alkaline phosphatase (ALP) activity, mineralization and the expression of osteogenesis-related genes of bone marrow stromal cells (BMSCs) were assessed. In vivo experiments involved constructing mouse THO models and tibial fracture models to evaluate the impact of PJ34 on ectopic bone formation and fracture healing. Results: In vitro, PJ34 dose-dependently inhibited BMSC proliferation, recruitment, migration, alkaline phosphatase (ALP) activity, and mineralization. In vivo, PJ34 significantly reduced heterotopic bone formation in a mouse THO model without impairing fracture healing. PJ34 also downregulated the expression of osteogenic genes (Runx2, BMP-2, ALP, OPN, BGLAP) in BMSCs. Conclusion: These findings preliminarily indicate that PJ34 prevents THO by inhibiting proliferation, migration, and osteogenic differentiation of BMSC, without adverse effects on normal bone healing. This supports PJ34's potential as a novel therapeutic agent for THO prevention, offering a safer alternative to current treatments, though further mechanistic validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.